| Literature DB >> 27346054 |
Mallikarjuna Rao Kovi1, Mohamed Abdelhalim1, Anil Kunapareddy1, Åshild Ergon1, Anne Marte Tronsmo1, May Bente Brurberg1,2, Ingerd Skow Hofgaard2, Torben Asp3, Odd Arne Rognli1.
Abstract
Lack of resistance to pink snow mould (Microdochium nivale) is a major constraint for adaptation of perennial ryegrass (Lolium perenne L.) to continental regions with long-lasting snow cover at higher latitudes. Almost all investigations of genetic variation in resistance have been performed using cold acclimated plants. However, there may be variation in resistance mechanisms that are functioning independently of cold acclimation. In this study our aim was to identify candidate genes involved in such resistance mechanisms. We first characterized variation in resistance to M. nivale among non-acclimated genotypes from the Norwegian cultivar 'Fagerlin' based on relative regrowth and fungal quantification by real-time qPCR. One resistant and one susceptible genotype were selected for transcriptome analysis using paired-end sequencing by Illumina Hiseq 2000. Transcriptome profiles, GO enrichment and KEGG pathway analysis indicate that defense response related genes are differentially expressed between the resistant and the susceptible genotype. A significant up-regulation of defense related genes, as well as genes involved in cell wall cellulose metabolic processes and aryl-alcohol dehydrogenase (NADP+) activity, was observed in the resistant genotype. The candidate genes identified in this study might be potential molecular marker resources for breeding perennial ryegrass cultivars with improved resistance to pink snow mould.Entities:
Mesh:
Year: 2016 PMID: 27346054 PMCID: PMC4921834 DOI: 10.1038/srep28702
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Resistance to M. nivale in 8 genotypes, measured as relative regrowth (dry weight of inoculated plants divided by dry weight of non-inoculated plants) after 6 and 8 weeks incubation under artificial snow cover followed by two weeks of regrowth.
Error bars indicate standard errors of the mean, and bars marked with different letters are significantly different (P < 0.05).
Figure 2Visual assessment of disease symptoms; scale 0 (no symptoms) to 4 (severely diseased), and amount of M. nivale (isolate 200231) DNA (pg. fungal DNA/ng plant DNA) in 8 genotypes of L. perenne cv.
Fagerlin after 6 and 8 weeks of inoculation. Error bars indicate standard errors of the mean, and bars marked with different letters are significantly different (P < 0.05).
Characteristics of the de novo transcriptome assemblies.
| Susceptible genotype (S) | Resistant genotype (R) | |
|---|---|---|
| Min. contig length (bp) | 201 | 201 |
| N50 (bp) | 1,784 | 1,672 |
| Max. contig length (bp) | 17,632 | 12,882 |
| Total no. of contigs | 261,978 | 188,355 |
| Sum of the reads | 178,000,000 | 165,000,000 |
Results of CEGMA analysis for de-novo assembly validation.
| Out of 248 CEGs | Resistant genotype (R) | Susceptible genotype (S) |
|---|---|---|
| % of fully represented | 82.66 | 93.95 |
| % of at least partially represented | 90.73 | 98.79 |
| Average number of orthologs per CEG | 3.72 | 3.83 |
| % of detected CEGs with more than 1 ortholog | 96.10 | 97.00 |
1CEGs: Core Eukaryotic Genes
Figure 3The number of differentially expressed transcripts identified using the de novo assembly method (A1) and the reference (inbred L. perenne transcriptome) based assembly method (A2) with FDR < 0.05. Venn diagrams showing the number of up-, down- and contra-regulated transcripts that were common and specific for the pairwise comparisons using the de novo assembly (B1) and the reference based assembly (B2). Contra-regulated transcripts are defined as transcripts upregulated in one condition, but downregulated in other condition. R; resistant genotype, S; susceptible genotype. NI-NI; non-inoculated and non-incubated plants, I-I; inoculated and incubated plants after 4 days of incubation, I-NI; non-inoculated and incubated plants after 4 days of incubation.
Figure 4Heat maps of differentially expressed genes detected using de novo assemblies and reference based assembly for each genotype and grouped according to their expression patterns.
X-axis represents the experimental conditions. R; resistant genotype, S; susceptible genotype. NI-NI; non- inoculated and non- incubated plants, I-I; inoculated and incubated plants after 4 days of incubation, I-NI; non-inoculated and incubated plants after 4 days of incubation.
Figure 5Gene ontology classifications of differentially expressed genes observed during pairwise comparisons of non-inoculated incubated (I-NI) and incubated inoculated (I-I) within resistant (R) and within susceptible (S) genotypes generated by WEGO tool http://wego.genomics.org.cn/cgi-bin/wego/index.pl) generated automatically by the web histogram tool WEGO (http://wego.genomics.org.cn/cgi-bin/wego/index.pl) using the newest GO archive provided.(
The results are summarized in three main GO categories: cellular component, molecular function and biological process. The right y-axis indicates the number of genes in a category. The left y-axis indicates the percentage of a specific category of genes in that main category.
Figure 6Annotation differences between resistant (R) and susceptible (S) genotypes detected by Fischer’s exact test.
List of differentially expressed genes that can be considered as potential candidate genes involved in response to M. nivale in two Lolium perenne, cv. Fagerlin genotypes, R (resistant genotype), and S (susceptible genotype).
| Sequence ID | Description | Log | Log | ||
|---|---|---|---|---|---|
| comp10786_c0_seq2 | Bradi1g36400.2 | 26s protease | 8.78 | −11.8 | |
| comp11656_c0_seq1 | AT3G08550.1 | Bradi2g07890.3 | Abscisic acid insensitive protein | −2.94 | 11.58 |
| comp11730_c0_seq1 | AT4G16830.3 | Bradi5g10027.1 | Abscisic acid protein | 10.98 | −0.36 |
| comp12003_c0_seq2 | AT4G16830.3 | Bradi5g10027.1 | Abscisic acid protein | −11.65 | −1.36 |
| comp13445_c0_seq1 | AT2G27730.1 | Bradi4g38600.2 | Atpase inhibitor protein | 10.06 | −11.4 |
| comp13446_c0_seq1 | AT5G62000.4 | Bradi2g59480.1 | Auxin response factor 2 | −0.05 | 11.57 |
| comp14875_c0_seq1 | AT5G62000.4 | Bradi2g59480.1 | Auxin response factor 2 | 11.15 | 11.57 |
| comp15074_c0_seq2 | AT1G56220.4 | Bradi4g31110.2 | Auxin-repressed protein | −4.60 | 11.96 |
| comp15317_c0_seq1 | AT2G41140.1 | Bradi1g61637.1 | Calcium -dependent protein kinase 1 | −0.51 | 7.07 |
| comp15765_c0_seq1 | AT5G23580.1 | Bradi4g24390.1 | Calcium-dependent protein kinase sk5 | 1.11 | 10.83 |
| comp16692_c0_seq1 | AT1G35670.1 | Bradi4g24390.1 | Calcium-dependent protein kinase sk5 | 8.36 | 9.74 |
| comp17044_c0_seq1 | AT5G57580.1 | Bradi3g05760.2 | Calmodulin binding protein | 0.37 | −10.5 |
| comp17054_c0_seq1 | AT3G49050.1 | Bradi2g00831.1 | Calmodulin-binding heat shock protein | 0.48 | −9.68 |
| comp17565_c0_seq2 | AT3G16920.1 | Bradi4g34040.1 | Chitinase 2 | −9.07 | 9.47 |
| comp22298_c0_seq1 | AT3G54420.1 | Bradi5g14430.1 | Chitinase 5 | 3.42 | 3.16 |
| comp23317_c0_seq2 | AT3G12500.1 | Bradi3g32340.1 | Class II chitinase | −0.71 | 3.26 |
| comp23443_c0_seq2 | AT2G02120.1 | Bradi3g49380.1 | Defensin precursor | −9.00 | 0.40 |
| comp23963_c0_seq1 | AT3G14470.1 | Bradi1g29560.2 | Disease resistance protein | 1.59 | 11.71 |
| comp24194_c0_seq2 | AT1G64160.1 | Bradi1g20185.1 | Disease resistance protein | 1.38 | 3.17 |
| comp24580_c0_seq2 | AT3G46730.1 | Bradi1g51961.2 | Disease resistance protein 3 | 7.97 | 3.57 |
| comp24988_c1_seq1 | AT1G72540.1 | Bradi1g51961.2 | Disease resistance protein 3 | 6.42 | −2.26 |
| comp25199_c0_seq1 | AT3G14460.1 | Bradi2g25327.1 | Disease resistance protein rga3 | 5.05 | −2.01 |
| comp26954_c0_seq8 | AT3G46730.1 | Bradi3g15593.1 | Disease resistance protein rpm1 | 9.76 | 8.47 |
| comp27012_c0_seq1 | AT3G46730.1 | Bradi4g24887.1 | Disease resistance protein rpm1 | 1.10 | 9.53 |
| comp27236_c0_seq2 | AT1G59780.1 | Bradi3g15593.2 | Disease resistance protein rpm1 | 12.59 | 6.93 |
| comp27390_c0_seq1 | AT3G07040.1 | Bradi4g35317.1 | Disease resistance protein rpm1 | 9.81 | 1.00 |
| comp27751_c0_seq17 | AT3G07040.1 | Bradi4g35317.1 | Disease resistance protein rpm1 | 11.93 | 2.13 |
| comp28444_c0_seq2 | AT1G58602.1 | Bradi4g21950.2 | Disease resistance protein rpp13 | −1.17 | 10.66 |
| comp28535_c0_seq2 | AT3G20770.1 | Bradi1g63780.1 | Ethylene signal transcription factor | 9.53 | 2.16 |
| comp28907_c0_seq3 | AT2G27050.1 | Bradi1g63780.1 | Ethylene signal transcription factor | 3.70 | −11.2 |
| comp28998_c0_seq2 | AT5G03280.1 | Bradi4g08380.1 | Ethylene-insensitive protein 2-like | 6.49 | 10.66 |
| comp29029_c0_seq9 | AT1G53910.3 | Bradi1g46690.3 | Ethylene-responsive transcription factor 1 | 0.25 | 2.03 |
| comp29851_c0_seq7 | AT3G14230.3 | Bradi2g02100.1 | Ethylene-responsive transcription factor crf4 | −9.85 | 0.94 |
| comp30083_c0_seq2 | AT1G53910.3 | Bradi1g46690.3 | Ethylene-responsive transcription factor rap2 | 2.42 | −0.74 |
| comp30409_c0_seq3 | AT1G55270.1 | Bradi3g01360.3 | F-box kelch-repeat protein | 0.85 | 12.01 |
| comp30635_c0_seq3 | Bradi3g31520.1 | F-box protein | 2.16 | −11.8 | |
| comp30748_c0_seq3 | AT2G42620.1 | Bradi1g49120.2 | F-box protein ore9-like | 0.54 | 9.56 |
| comp30853_c0_seq1 | AT2G24270.4 | Bradi3g36930.1 | Glyceraldehyde-3-phosphate dehydrogenase | 12.60 | −12.8 |
| comp30959_c0_seq10 | AT3G25530.1 | Bradi3g46080.1 | Glyoxylate reductase 1 | 4.57 | 11.89 |
| comp31014_c0_seq1 | AT5G02500.1 | Bradi1g03720.1 | Heat shock protein 70 | 5.10 | 13.11 |
| comp31072_c0_seq5 | AT5G02500.1 | Bradi1g03720.1 | Heat shock protein 70 | 4.02 | 12.15 |
| comp31301_c0_seq19 | AT5G63890.1 | Bradi1g17340.1 | Histidinol dehydrogenase | 1.37 | −12.7 |
| comp31318_c0_seq3 | AT4G14420.1 | Bradi1g75100.2 | HR-like lesion-inducing protein | 4.10 | −12.7 |
| comp31337_c1_seq2 | AT1G15690.2 | Bradi1g30550.1 | Inorganic H pyrophosphatase protein | −4.93 | 13.84 |
| comp31380_c0_seq1 | AT2G38540.1 | Bradi4g25750.1 | Lipid transfer protein | −1.76 | 3.91 |
| comp31450_c0_seq51 | AT2G38540.1 | Bradi4g25750.1 | Lipid transfer protein | −2.82 | 1.86 |
| comp31553_c0_seq3 | AT2G42880.1 | Bradi2g45870.1 | MAP kinase protein | 12.53 | −0.05 |
| comp31649_c0_seq29 | AT3G55270.1 | Bradi2g37450.2 | MAP kinase phosphatase | 13.85 | −0.09 |
| comp31684_c0_seq5 | AT5G56580.1 | Bradi1g75150.1 | MAP kinase protein | 12.57 | −3.52 |
| comp31934_c0_seq20 | AT1G53570.5 | Bradi3g45790.1 | MAPkkk protein kinase | 0.47 | 0.57 |
| comp31966_c0_seq4 | AT1G53570.2 | Bradi5g10670.2 | MAPkkk protein kinase | 10.90 | 0.28 |
| comp31978_c0_seq6 | AT1G07180.1 | Bradi2g53970.1 | NAD(P)H dehydrogenase 1 | 0.06 | 12.56 |
| comp32014_c0_seq2 | AT3G14470.1 | Bradi1g29560.2 | NB-ARC disease resistance protein | 2.33 | -7.97 |
| comp32363_c0_seq37 | AT4G26090.1 | Bradi5g15560.1 | NB-ARC disease resistance protein | 8.92 | 1.35 |
| comp33360_c0_seq1 | AT2G26040.1 | Bradi1g64920.1 | Pathogenesis-related protein 1 | −1.44 | 12.21 |
| comp33451_c0_seq1 | AT4G25780.1 | Bradi1g57540.1 | Pathogenesis-related protein 1 | 1.75 | 4.48 |
| comp33568_c0_seq1 | AT3G04720.1 | Bradi4g14930.1 | Pathogenesis-related protein 4 | −3.31 | 1.58 |
| comp34254_c0_seq1 | AT1G75050.1 | Bradi4g05440.1 | Pathogenesis-related protein 5 | 0.50 | 5.60 |
| comp34926_c0_seq1 | AT1G78780.2 | Bradi2g08707.1 | Pathogen-related protein | −8.18 | 0.37 |
| comp35213_c0_seq1 | AT1G09570.2 | Bradi1g10520.2 | Phytochrome A | −5.79 | −10.4 |
| comp35885_c0_seq1 | AT4G35470.1 | Bradi3g33990.1 | Plant intracellular ras group-related LRR 4 | 9.20 | 12.03 |
| comp35990_c0_seq1 | AT1G64060.1 | Bradi2g19090.5 | Respiratory burst oxidase protein 2 | −0.48 | 9.35 |
| comp36198_c0_seq1 | AT2G39840.1 | Bradi3g55614.3 | Serine threonine protein phosphatase pp1 | 3.01 | −12.06 |
| comp36434_c0_seq1 | AT2G39840.1 | Bradi3g55614.3 | Serine threonine protein phosphatase pp1 | 3.03 | −11.4 |
| comp37190_c0_seq1 | AT4G33950.1 | Bradi1g07620.1 | Serine threonine-protein kinase | 1.24 | −0.32 |
| comp38150_c0_seq1 | AT3G13380.1 | Bradi4g27440.1 | Serine threonine-protein kinase | −0.28 | 0.37 |
| comp41496_c0_seq1 | AT4G33080.1 | Bradi2g33530.2 | Serine threonine-protein kinase cbk1 | −1.22 | −8.39 |
| comp42382_c0_seq1 | AT4G33080.2 | Bradi2g33530.1 | Serine threonine-protein kinase cbk1 | −1.84 | −8.13 |
| comp43183_c0_seq1 | AT5G02800.1 | Bradi1g76362.2 | Serine threonine-protein kinase pbs1 | 0.06 | −9.37 |
| comp44101_c0_seq1 | AT5G22840.1 | Bradi1g08660.2 | Serine threonine-protein kinase srpk2 | 10.60 | −1.25 |
| comp45052_c0_seq1 | AT2G13360.1 | Bradi3g39750.2 | Serine-glyoxylate aminotransferase | −0.71 | 1.41 |
| comp46601_c0_seq1 | AT3G15610.1 | Bradi1g36840.1 | Serine-threonine kinase receptor-associated | 1.95 | −4.15 |
| comp48325_c0_seq1 | AT2G45950.1 | Bradi1g62007.1 | SKP1-like protein 21 | −1.25 | 8.57 |
| comp49870_c0_seq1 | AT4G11650.1 | Bradi4g05440.1 | Thaumatin domain family protein | −9.07 | 12.16 |
| comp5056_c0_seq1 | AT4G11650.1 | Bradi3g07960.1 | Thaumatin pathogenesis-related protein 3 | −9.96 | 3.14 |
| comp64771_c0_seq1 | AT2G02760.1 | Bradi2g05400.2 | Ubiquiting-conjugating enzyme 2 | −1.97 | 13.67 |
| comp6936_c0_seq1 | AT4G31800.2 | Bradi1g30870.1 | WRKY DNA-binding protein 18 | −9.91 | −2.84 |
| comp73317_c0_seq1 | AT4G31800.2 | Bradi3g06070.1 | WRKY DNA-binding protein 18 | 1.95 | −1.39 |
| comp7627_c0_seq1 | AT5G56270.1 | Bradi4g33370.1 | WRKY DNA-binding protein 2 | −10.43 | 10.95 |
| comp76423_c0_seq1 | AT2G38470.1 | Bradi2g00280.1 | WRKY DNA-binding protein 33 | 2.32 | −5.45 |
| comp7959_c0_seq1 | AT5G64810.1 | Bradi2g18530.1 | WRKY DNA-binding protein 51 | 4.05 | 0.34 |
| comp8111_c0_seq1 | AT1G29280.1 | Bradi2g49906.1 | WRKY DNA-binding protein 65 | −8.24 | 0.05 |
| comp8129_c0_seq1 | AT2G46400.1 | Bradi1g17660.1 | WRKY DNA-binding protein 70 | −0.47 | 1.84 |
| comp8631_c0_seq2 | AT5G13080.1 | Bradi4g19060.1 | WRKY DNA-binding protein 75 | 0.53 | 1.49 |
| comp8708_c0_seq1 | AT3G55980.1 | Bradi4g05990.2 | Zinc finger protein 33 | −0.97 | 9.28 |
| comp8930_c0_seq1 | AT2G16485.1 | Bradi4g35977.2 | Zinc finger protein 44 | −2.49 | 0.13 |
| comp9122_c0_seq1 | AT2G27580.1 | Bradi1g06036.1 | Zinc finger stress-associated protein 6 | 0.39 | 9.21 |
| comp9340_c0_seq1 | AT1G07360.1 | Bradi1g48140.1 | Zinc finger protein 40 | 0.20 | −9.68 |
| comp9759_c0_seq1 | AT3G12630.1 | Bradi3g39850.1 | Zinc finger stress-associated protein 5 | −10.85 | −9.95 |
aThe log2 of the fold change between the resistant (R) and susceptible (S) genotype under non-inoculated and incubated conditions after 4 days of incubation (I-NI).
bThe log2 of the fold change between the resistant (R) and susceptible (S) genotype under inoculated and incubated (I-I) conditions after 4 days of incubation.
Figure 7Hypothetical modules for plant-pathogen interaction after 4 days of incubation with snow mould pathogen M. nivale derived by KEGG plant-pathogen interaction pathway (http://www.genome.jp/kegg/) and network of WRKY transcription factors (Eulgem & Somssich (2007).
Red color indicates down regulated genes and green color indicates up-regulated genes. Intensity of the colors indicates the fold change. Circle represents the fold change under non-inoculated and incubated, condition (I-NI) a. The square represents the fold change under inoculated, incubated (I-I) b conditions. The recognition of pathogen-associated molecular pattern (PAMP) initiate PAMP trigger immunity via the activation of cysteine-rich receptor-like protein kinase (CRK), cyclic nucleotide gated channel (CNGC), calcium-dependent protein kinase (CDPK), respiratory burst oxidase homolog (Rboh), calcium-binding protein CML (CaM/CML), and NADPH oxidase. The activation of PAMP trigger immunity initiate the production of reactive oxygen species (ROS), which might activate the plant hypersensitive response (HR), cell wall reinforcement, as well as stomata closure. Defense responses are also instigated upon recognition of the fungal effectors in the host cell by serine/threonine-protein kinase PBS (PBS) and the activation of MAP kinase cascades such as mitogen-activated protein kinase kinase kinase (MAPKKK), mitogen-activated protein kinase kinase (MAPKK), and mitogen-activated protein kinase (MAPK). Effectors triggered immunity (ETI) initiate the production of several pathogen related proteins such as PR-1, β-1,3-glucanase (PR-2), chitinase II/V (PR-3), thaumatin-like (PR-5), and lipid-transfer protein (PR-14). Both PAMP triggered immunity and effectors triggered immunity alternate the production of salicylic acid (SA) and jasmonic acid (JA) by the action of distinct transcription factors WRKY such as WRKY 75, WRKY 70, WRKY 18, and WRKY 33. Pathogen-triggered SA signaling also by the activation of serine/threonine-protein kinase2 (SRK2), auxin receptors, and abscisic acid responsive element binding factor (ABF).